From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery

被引：831
作者：
Banks, William A. [1 ,2 ]
机构：
[1] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA
[2] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, 1660 S Columbian Way, Seattle, WA 98108 USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2016年 / 15卷 / 04期
关键词：
AMYLOID-BETA-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; RECEPTOR-RELATED PROTEIN-1; MOUSE CEREBRAL PERICYTES; NECROSIS-FACTOR-ALPHA; SPINAL-CORD BARRIER; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; ENDOTHELIAL-CELLS; P-GLYCOPROTEIN;
D O I：
10.1038/nrd.2015.21
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
One of the biggest challenges in the development of therapeutics for central nervous system (CNS) disorders is achieving sufficient blood-brain barrier (BBB) penetration. Research in the past few decades has revealed that the BBB is not only a substantial barrier for drug delivery to the CNS but also a complex, dynamic interface that adapts to the needs of the CNS, responds to physiological changes, and is affected by and can even promote disease. This complexity confounds simple strategies for drug delivery to the CNS, but provides a wealth of opportunities and approaches for drug development. Here, I review some of the most important areas that have recently redefined the BBB and discuss how they can be applied to the development of CNS therapeutics.
引用
收藏
页码：275 / +
页数：18
相关论文
共 175 条
[31]   Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-α in the rat [J].
Candelario-Jalil, Eduardo ;
Taheri, Saeid ;
Yang, Yi ;
Sood, Rohit ;
Grossetete, Mark ;
Estrada, Eduardo Y. ;
Fiebich, Bernd L. ;
Rosenberg, Gary A. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 323 (02) :488-498
[32]   Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain [J].
Cao, CY ;
Matsumura, K ;
Yamagata, K ;
Watanabe, Y .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1997, 272 (06) :R1712-R1725
[33]   FATTY-ACID ACYLATED FAB-FRAGMENTS OF ANTIBODIES TO NEUROSPECIFIC PROTEINS AS CARRIERS FOR NEUROLEPTIC TARGETED DELIVERY IN BRAIN [J].
CHEKHONIN, VP ;
KABANOV, AV ;
ZHIRKOV, YA ;
MOROZOV, GV .
FEBS LETTERS, 1991, 287 (1-2) :149-152
[34]   Central Nervous System Penetration for Small Molecule Therapeutic Agents Does Not Increase in Multiple Sclerosis- and Alzheimer's Disease-Related Animal Models Despite Reported Blood-Brain Barrier Disruption [J].
Cheng, Ziqiang ;
Zhang, Jinqiang ;
Liu, Houfu ;
Li, Yi ;
Zhao, Yonggang ;
Yang, Eric .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (08) :1355-1361
[35]  
CHIKHALE EG, 1995, J PHARMACOL EXP THER, V273, P298
[36]   HYDROGEN-BONDING POTENTIAL AS A DETERMINANT OF THE IN-VITRO AND IN-SITU BLOOD-BRAIN-BARRIER PERMEABILITY OF PEPTIDES [J].
CHIKHALE, EG ;
NG, KY ;
BURTON, PS ;
BORCHARDT, RT .
PHARMACEUTICAL RESEARCH, 1994, 11 (03) :412-419
[37]   Cutting Edge: Natalizumab Blocks Adhesion but Not initial Contact of Human T Cells to the Blood-Brain Barrier In Vivo in an Animal Model of Multiple Sclerosis [J].
Coisne, Caroline ;
Mao, Wenxian ;
Engelhardt, Britta .
JOURNAL OF IMMUNOLOGY, 2009, 182 (10) :5909-5913
[38]   COMPARISON OF LIPID-MEDIATED BLOOD-BRAIN-BARRIER PENETRABILITY IN NEONATES AND ADULTS [J].
CORNFORD, EM ;
BRAUN, LD ;
OLDENDORF, WH ;
HILL, MA .
AMERICAN JOURNAL OF PHYSIOLOGY, 1982, 243 (03) :C161-C168
[39]   The blood-brain-barrier in multiple sclerosis: Functional roles and therapeutic targeting [J].
Correale, Jorge ;
Villa, Andres .
AUTOIMMUNITY, 2007, 40 (02) :148-160
[40]   Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease - Relationship to severity of dementia and apolipoprotein E genotype [J].
Craft, S ;
Peskind, E ;
Schwartz, MW ;
Schellenberg, GD ;
Raskind, M ;
Porte, D .
NEUROLOGY, 1998, 50 (01) :164-168
12345678910